Centrient Pharmaceuticals

Antibiotics Cannot Be Taken For Granted’ – Centrient’s CEO, Rex Clements, in an interview with Generics Bulletin, on ensuring a sustainable industry: insights.citeline.com/generics-bulle…

Hear from our CEO Rex Clements in his BBC interview as he tackles the urgent challenges shaping the pharmaceutical industry - from trade disruptions to medicine supply resilience: bbc.com/audio/play/p0l…

Effective September 1, 2025, Centrient has appointed Pierre-Yves Dalla-Libera as the new manufacturing Site Director for Delft.

Recently wrapped up a productive visit to Brussels, tackling one of Europe’s biggest health challenges: antibiotic supply. Centrient is ready to lead—with scale, expertise, and commitment to resilient manufacturing in Europe and we are proud to be part of the solution.

Curious to learn more about the importance of Centrient's manufacturing site in Delft, the Netherlands? Read more below. linkedin.com/feed/update/ur…

Keeping medicine manufacturing strong in Europe is crucial for a reliable supply of critical medicines. Read from our CEO, Rex Clements, on his perspective on the growing challenges manufacturers face and how Centrient is addressing them: centrient.com/media/lets-not…

Centrient supports the recommendations of the Critical Medicines Alliance in its recently released strategic report, emphasizing the importance of strengthening European pharmaceutical supply chains and ensuring the availability of critical medicines: centrient.com/media/centrien…

Effective Jan 2025, Centrient is proud to announce the appointment of Phil Wieland as the new Chairman of its Supervisory Board of Directors. Mr. Wieland will better position Centrient to continue delivering on its mission to provide sustainable solutions & life-saving medicines.

Centrient is proud to announce that, for the fifth year in a row, it has received a Gold sustainability rating from EcoVadis! The 2024 Gold rating ranks Centrient within the top 5% of all companies assessed by EcoVadis.